Practical Approach to Cardiovascular Disease: From Prevention to Intervention (Multiple Modules)
This series addresses how to identify the patient population at highest risk for developing cardiovascular disease and acute cardiovascular events; how to approach this population in terms of laboratory testing, calcium scoring and overall patient care management; and how to decrease the possibilities of acute coronary events in these patients.
• How do I apply the current guidelines?
• What is the connection between sugar, obesity and cardiovascular disease?
• What are the most common clinical scenarios seen in clinical practice and how do I apply the evidence?
• What is residual risk?
Instructions: Select topic below to view additional details and to enroll.
|Course Topics and Faculty||Credits|
|Excercise as a Therapeutic Agent in the 21st Century |
Carl “Chip” J. Lavie Jr., M.D., FACC, FACP, FCCP
|Exercise Prescription for Primary and Secondary Prevention |
Michael J. Blaha, M.D., MPH
|Familial Hypercholesterolemia: Clinical Update|
Paul E. Ziajka, M.D., Ph.D., FNL
|FOURIER: Extensive Lipid Lowering (PCSK9) |
Christie M. Ballantyne, M.D.
|Fructose and Metabolic Syndrome: Is There a Link? |
Robert H. Lustig, M.D.
|SPRINTing to the 2017 Hypertension Guidelines |
Roger Blumenthal, M.D.
|Metabolic Syndrome: Prevention and Management Strategies |
Roger Blumenthal, M.D.
|Obesity: Beyond Lifestyle and Bariatric Surgery|
Theodore Feldman, M.D.
|Omega-3 Fatty Acids and Cardiometabolic Health |
Michael Ozner, M.D.
|Practical Medicine: Cardiometabolic Disease|
Round Table Discussions - Interview With the Experts Including Practical Tips for the Busy Practitioner
Christie M. Ballantyne, M.D., Michael J. Blaha, M.D., Roger Blumenthal, M.D., Theodore Feldman, M.D. and Michael Ozner, M.D.
|From Xanthomata to Coronary Artery Disease: The Trail to the LDL Receptor|
William Virgil Brown, M.D.
|Resistant Hypertension: Management Strategies|
William C. Cushman, M.D.
Cardiovascular Disease Prevention Specialists, Lipidologists, Cardiologists, Family Medicine Physicians, General Internists, Endocrinologists, Gynecologists, Nurses, Nursing Practitioners and Physician Assistants.
- Implement practical approaches to common and important cardiometabolic challenges utilizing the latest evidence-based screening guidelines and treatment approaches to achieve reduction of cardiovascular disease risk.
See individual course pages for faculty titles and disclosure information.
PLANNERS - 2018 Cardiometabolic Symposium
Theodore Feldman, M.D., symposium director, has disclosed that he is a member of the speaker’s bureau for Amgen, Boehringer Ingelheim Pharmaceuticals, Novartis Pharmaceuticals, NovoNordisk and Regeneron/Sanofi, and that he serves as a consultant to Merck. Dr. Feldman has indicated that his presentation will not include discussion of off-label or unapproved usage.
Khurram Nasir, M.D., symposium director, has disclosed that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and they will not include off-label or unapproved product usage in their presentations or discussions.
Michael D. Ozner, M.D., FACC, FAHA has disclosed that he is a member of the scientific advisory board for the Life Extension Foundation, and Author of the books The Great American Heart Hoax, Heart Attack Proof, and The Complete Mediterranean Diet. Dr. Ozner has indicated that his presentation will not include discussion of off-label or unapproved usage.
All other non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.
See individual module pages for applicable credits and accreditations.